Precigen completes $170M sale of Trans Ova Genetics; pro forma shows $213M cash

PRECIGEN, INC.

Closed sale of 100% of Trans Ova to Spring Bidco LLC for $170M; net cash proceeds ~$169.5M.
Pro forma cash and equivalents rise to $213.4M from $43.8M as of June 30, 2022.
Pro forma continuing ops loss of $49.2M for H1 2022 vs. historical loss of $36.9M (net of discontinued ops).
Pro forma continuing ops loss of $110.8M for FY2021, compared to historical net loss of $96.8M.
Pro forma balance sheet eliminates $88.9M of assets and $15.1M of liabilities classified as held for sale.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.